Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

References

• MiravitllesMSorianoJBGarcia-RioRPrevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activitiesThorax2009641086386819553233
   PubMed Web of Science ®Google Scholar
• MurrayCJVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592197222323245608
   PubMed Web of Science ®Google Scholar
• DransfieldMTBaileyWCraterGEmmettAO’DellDMYawnBDisease severity and symptoms among patients receiving monotherapy for COPDPrim Care Respir J2011201465320886200
   PubMedGoogle Scholar
• NishimuraKIzumiJTsukinaMOgaJDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest200212151434144012006425
   PubMed Web of Science ®Google Scholar
• BurgelPREscamillaRPerezTImpact of comorbidities on COPD-specific health related quality of lifeRespir Med2013107223324123098687
   PubMed Web of Science ®Google Scholar
• MiravitllesMMurioCGuerreroTGisbertRCost of chronic bronchitis and COPD. A 1-year follow-up studyChest2003123378479112628879
   PubMed Web of Science ®Google Scholar
• Goldcopd.org [homepage on the internet]Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2014 Available from: http://www.goldcopd.orgAccessed July 1, 2015
   Google Scholar
• MiravitllesMSoler-CataluñaJJCalleMSpanish Guidelines for COPD (GesEPOC) Update 2014Arch Bronconeumol201450Suppl 111624507959
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Equality and Social Policy [Anoro® 55/22 mcg powder for inhalation]Data Sheet. [database on the Internet] Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm.SpanishAccessed July 1, 2015
   Google Scholar
• Catalá-LópezFGarcía-AltésAAlvarez-MartínEGènova-MalerasRMorant-GinestarCParadaABurden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?BMC Health Serv Res2011117521489236
   PubMed Web of Science ®Google Scholar
• Gonzalez-McQuireSTabbererMMuellerovaHBriggsALomasDRutten-van MölkenMDevelopment of a conceptual model for use in economic modeling of chronic obstructive pulmonary diseaseValue Health2012157A470
   Web of Science ®Google Scholar
• Lopez-BastidaJOlivaJAntoñanzasFA proposed guideline for economic evaluation of health technologiesGac Sanit2010242154170 Spanish19959258
   PubMed Web of Science ®Google Scholar
• McGahnWFMaiwennALDoshiJAKamaeIMarxSERindressDThe ISPOR good practice for quality improvement of cost-effectiveness research task force reportValue Health20091281086109919744291
   PubMed Web of Science ®Google Scholar
• VestboJAndersonWCoxsonHOEvaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)Eur Respir J200831486987318216052
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• ExuzidesAColbyCBriggsAStatistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE StudyMed Decis Making Epub2015108
   Web of Science ®Google Scholar
• Rutten-van MölkenMPGoossensLMCost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issuesPharmacoeconomics201230427130222409290
   PubMed Web of Science ®Google Scholar
• IMS Heath databases [Medical dispensing database]Total annual moving (MAT) April 2014–2015 Available from: http://www.imshealth.comAccessed December 17, 2015
   Google Scholar
• CasanovaCMarinJMMartinez-GonzalezCNew GOLD classification: longitudinal data on group assignmentRespir Res201415324417879
   PubMed Web of Science ®Google Scholar
• AlmagroPMartinez-CamblorPSorianoJBFinding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS studyPLoS One201492e8986624587085
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Equality and Social Policy [Spanish National Health Survey 2011–12] [database on the Internet]. Available from: http://www.msssi.gob.es/estadEstudios/estadisticas/encuestaNacional/encuesta2011.htmAccessed July 1, 2015 Spanish
   Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• StarkieHJBriggsAHChambersMGJonesPPredicting EQ-5D values using the SGRQValue Health201114235436021402304
   PubMed Web of Science ®Google Scholar
• MiravitllesMHuertaAFernandez-VillarJGeneric utilities in chronic obstructive pulmonary disease patients stratified according to different staging systemsHealth Qual Life Outcomes20141212025189786
   PubMed Web of Science ®Google Scholar
• MiravitllesMHuertaAValleMClinical variables impacting on the estimation of utilities in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151036737725733826
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Equality and Social Policy [Catalogue of sanitarian products included in the Spanish National Health System pharmaceutical provision]42015 [database on the Internet]. Available from: http://www.msssi.gob.es/profesionales/nomenclator.doAccessed July 1, 2015 Spanish
   Google Scholar
• MiravitllesMMurioCGuerreroTGisbertRDAFNE Study GroupPharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPDChest200212151449145512006427
   PubMed Web of Science ®Google Scholar
• MiravitllesMGarcia-PoloCDomenechAVillegasGCongetFde la RozaCClinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary diseaseLung2013191552353023842641
   PubMed Web of Science ®Google Scholar
• PunekarYSShuklaAMüllerovaHCOPD management costs according to the frequency of COPD exacerbations in UK primary careInt J Chron Obstruct Pulmon Dis20149657324426781
   PubMed Web of Science ®Google Scholar
• SicrasAHuertaANavarroRIbañezJUse of resources and costs associated with the exacerbations of chronic obstructive pulmonary disease: a retrospective population-based studySemergen2014404189197 Spanish24485969
   PubMedGoogle Scholar
• BriggsAHHandling uncertainty in cost-effectiveness modelsPharmacoeconomics200017547950010977389
   PubMed Web of Science ®Google Scholar
• DecramerMAnuzetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapy over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• SacristanJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit2002164334343 Spanish12113733
   PubMedGoogle Scholar
• De CockEMiravitllesMGonzalez-JuanateyJRAzanza-PereaJRThreshold value of the cost per year of life gained to recommend the adoption of health technologies in Spain: evidence from a reviewPharmacoeconomics20074397107 Spanish
   Google Scholar
• De LucasPMiravitllesMRodriguezJMde MiguelJLopezSSanchezGCost-effectiveness analysis of tiotropium versus ipratropium in the treatment of COPD patientsPharmacoeconomics200413123130 Spanish
   Google Scholar
• Rutten-van MölkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
   PubMed Web of Science ®Google Scholar
• BrosaMDiaz-CerezoSMiravitllesMGonzalez-RojasNNievesDCost-effectiveness analysis of tiotropium in the treatment of COPD in SpainPharmacoeconomics201071312 Spanish
   Google Scholar
• BrosaMPerez-AlcantaraFBorderias-ClauLGaldiz-IturriJBRiera-FebrerMFigueres-SabateMCost-utility anaysis of indacaterol versus tiotropium in the treatment of COPD in SpainPharmacoeconomics2013108997 Spanish
   Google Scholar
• PunekarYSRobertsGIsmailaAO’LeayMCost-effectiveness of umeclidinium/vilanterol combination therapy among symptomatic COPD patientsValue Health2014177A595
   Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LAMA/LABA dual bronchodilator indacaterol/glycopirronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• HoogendoornMFeenstraTLAsukaiYCost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosValue Health201417552553625128045
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoALocantoreNSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar